02420nam a2200325 a 4500 ebr10641813 CaPaEBR m o u cr cn||||||||| 121010s2013 njuad sb 001 0 eng d 2012032915 9781118487471 (pbk.) 9781118511299 (e-book) CaPaEBR CaPaEBR (OCoLC)831464032 HD9665.5 .L36 2013eb 338.4/76151 23 LaMattina, John L. Devalued and distrusted [electronic resource] : can the pharmaceutical industry restore its broken image? / John L. LaMattina. Hoboken, N.J. : Wiley, 2013. ix, 125 p. : col. ill. Includes bibliographical references and index. Machine generated contents note: Introduction Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know" Part 2. What Has Happened to R&D Productivity? a. Impact of Mergers b. Impact of FDA c. Impact of Payers Part 3. Challenges in Key Therapeutic Areas for Improving Health a. Cancer b. Diseases of the Brain c. Cardiovascular Disease d. Diabetes e. Bacterial Infections Part 4. Improving R&D Output a. View of Others b. Personal Vision Part 5. Restoring the Pharma Image Part 6. Final Thoughts. "While the pharmaceutical industry can play an important role in converting the knowledge generated by the Human Genome Project into new medicines, it also faces a popular perception that it is simply out to make money by promoting unsafe medicines to an unsuspecting public. Written by former Pfizer president John LaMattina, this book addresses the progress that the industry has made in improving its abilities to measure both the risk and benefits of its new medicines, where the industry should invest its R&D resources, and how the industry can rehabilitate its image. Essential reading for pharmaceutical executives and professionals"-- Provided by publisher. Electronic reproduction. Palo Alto, Calif. : ebrary, 2015. Available via World Wide Web. Access may be limited to ebrary affiliated libraries. Pharmaceutical industry Corrupt practices. Electronic books. local ebrary, Inc. http://site.ebrary.com/lib/rucke/Doc?id=10641813 An electronic book accessible through the World Wide Web; click to view 31778 31778